282 related articles for article (PubMed ID: 23403951)
1. Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition.
Antoon JW; Nitzchke AM; Martin EC; Rhodes LV; Nam S; Wadsworth S; Salvo VA; Elliott S; Collins-Burow B; Nephew KP; Burow ME
Int J Oncol; 2013 Apr; 42(4):1139-50. PubMed ID: 23403951
[TBL] [Abstract][Full Text] [Related]
2. Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.
Milone MR; Pucci B; Bruzzese F; Carbone C; Piro G; Costantini S; Capone F; Leone A; Di Gennaro E; Caraglia M; Budillon A
Cell Death Dis; 2013 May; 4(5):e641. PubMed ID: 23703386
[TBL] [Abstract][Full Text] [Related]
3. Epithelial to mesenchymal transition is associated with rapamycin resistance.
Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
[TBL] [Abstract][Full Text] [Related]
4. Roles of p38 MAPK and JNK in TGF-β1-induced human alveolar epithelial to mesenchymal transition.
Chen HH; Zhou XL; Shi YL; Yang J
Arch Med Res; 2013 Feb; 44(2):93-8. PubMed ID: 23376055
[TBL] [Abstract][Full Text] [Related]
5. ROR2 promotes the epithelial-mesenchymal transition by regulating MAPK/p38 signaling pathway in breast cancer.
Xu J; Shi J; Tang W; Jiang P; Guo M; Zhang B; Ma G
J Cell Biochem; 2020 Oct; 121(10):4142-4153. PubMed ID: 32048761
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide gene expression analysis of a murine model of prostate cancer progression: Deciphering the roles of IL-6 and p38 MAPK as potential therapeutic targets.
Daouk R; Bahmad HF; Saleh E; Monzer A; Ballout F; Kadara H; Abou-Kheir W
PLoS One; 2020; 15(8):e0237442. PubMed ID: 32790767
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation.
Antoon JW; Bratton MR; Guillot LM; Wadsworth S; Salvo VA; Burow ME
Cancer Biol Ther; 2012 Sep; 13(11):1026-33. PubMed ID: 22825349
[TBL] [Abstract][Full Text] [Related]
8. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
Brown WS; Akhand SS; Wendt MK
Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
[TBL] [Abstract][Full Text] [Related]
9. p38 MAPK is Crucial for Wnt1- and LiCl-Induced Epithelial Mesenchymal Transition.
Fang CX; Ma CM; Jiang L; Wang XM; Zhang N; Ma JN; Wu TH; Zhang ZH; Zhao GD; Zhao YD
Curr Med Sci; 2018 Jun; 38(3):473-481. PubMed ID: 30074215
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells.
Han X; Chen H; Zhou J; Steed H; Postovit LM; Fu Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30049957
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-mesenchymal transition regulated by p38/MAPK signaling pathways participates in vasculogenic mimicry formation in SHG44 cells transfected with TGF-β cDNA loaded lentivirus in vitro and in vivo.
Ling G; Ji Q; Ye W; Ma D; Wang Y
Int J Oncol; 2016 Dec; 49(6):2387-2398. PubMed ID: 27748800
[TBL] [Abstract][Full Text] [Related]
12. The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells.
Li JP; Yang YX; Liu QL; Zhou ZW; Pan ST; He ZX; Zhang X; Yang T; Pan SY; Duan W; He SM; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1027-62. PubMed ID: 25733818
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.
Zhou C; Nitschke AM; Xiong W; Zhang Q; Tang Y; Bloch M; Elliott S; Zhu Y; Bazzone L; Yu D; Weldon CB; Schiff R; McLachlan JA; Beckman BS; Wiese TE; Nephew KP; Shan B; Burow ME; Wang G
Breast Cancer Res; 2008; 10(6):R105. PubMed ID: 19087274
[TBL] [Abstract][Full Text] [Related]
14. CTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway.
Ke J; Han W; Meng F; Guo F; Wang Y; Wang L
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830111
[TBL] [Abstract][Full Text] [Related]
15. Schisandrin B inhibits epithelial‑mesenchymal transition and stemness of large‑cell lung cancer cells and tumorigenesis in xenografts via inhibiting the NF‑κB and p38 MAPK signaling pathways.
Li S; Wang H; Ma R; Wang L
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33907830
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth.
Werden SJ; Sphyris N; Sarkar TR; Paranjape AN; LaBaff AM; Taube JH; Hollier BG; Ramirez-Peña EQ; Soundararajan R; den Hollander P; Powell E; Echeverria GV; Miura N; Chang JT; Piwnica-Worms H; Rosen JM; Mani SA
Oncogene; 2016 Nov; 35(46):5977-5988. PubMed ID: 27292262
[TBL] [Abstract][Full Text] [Related]
17. Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance.
Antoon JW; Lai R; Struckhoff AP; Nitschke AM; Elliott S; Martin EC; Rhodes LV; Yoon NS; Salvo VA; Shan B; Beckman BS; Nephew KP; Burow ME
Sci Rep; 2012; 2():539. PubMed ID: 22844580
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of invasion and epithelial-mesenchymal transition of human breast cancer cells by hydrogen sulfide through decreased phospho-p38 expression.
Lv M; Li Y; Ji MH; Zhuang M; Tang JH
Mol Med Rep; 2014 Jul; 10(1):341-6. PubMed ID: 24756435
[TBL] [Abstract][Full Text] [Related]
19. The N-terminal polypeptide derived from viral macrophage inflammatory protein II reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanism.
Yang QL; Zhang LY; Wang HF; Li Y; Wang YY; Chen TT; Dai MF; Wu HH; Chen SL; Wang WR; Wu Q; Chen CJ; Zhou CZ
Oncotarget; 2017 Jun; 8(23):37448-37463. PubMed ID: 28415580
[TBL] [Abstract][Full Text] [Related]
20. p38 maintains E-cadherin expression by modulating TAK1-NF-kappa B during epithelial-to-mesenchymal transition.
Strippoli R; Benedicto I; Foronda M; Perez-Lozano ML; Sánchez-Perales S; López-Cabrera M; Del Pozo MÁ
J Cell Sci; 2010 Dec; 123(Pt 24):4321-31. PubMed ID: 21098640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
